• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates

    6/29/23 2:32:01 PM ET
    $AYI
    $BTAI
    $GNLN
    $IMNM
    Building Products
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AYI alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday.

    The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P 500, also rose, gaining, 0.28% to 4,389.22.

    Check This Out: Check Out 3 High-Yielding Dividend Stocks In Materials Sector From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

    • Financials shares jumped by 1.5% on Thursday.

    In trading on Thursday, communication services shares fell by 0.6%.

     

    Top Headline

    Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings for its third quarter on Thursday.

    Acuity Brands reported a third-quarter FY23 net sales decline of 5.7% year-over-year to $1.0 billion, missing the consensus of $1.05 billion. Adjusted EPS of $3.75 beat the consensus of $3.71.

     

    Equities Trading UP

    • Sigilon Therapeutics, Inc. (NASDAQ:SGTX) shares shot up 505% to $23.67 after Eli Lilly agreed to acquire the company for $14.92/share in cash.
    • Shares of Eco Wave Power Global AB (NASDAQ:WAVE) got a boost, shooting 23% to $1.9206 after the company announced plans for a share repurchase program of up to 10% of the total number of shares in the company.
    • Immunome, Inc. (NASDAQ:IMNM) shares were also up, gaining 34% to $7.90 after the company and Morphimmune announced a definitive merger agreement and simultaneous private placement investment of $125 million to develop targeted cancer therapies.

     

    Equities Trading DOWN

    • BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares dropped 66% to $6.08 after the company released topline results from TRANQUILITY II Phase 3 trial of BXCL501 for acute treatment of Alzheimer's Disease-related agitation.
    • Shares of Greenlane Holdings, Inc. (NASDAQ:GNLN) were down 25% to $1.00 after announcing a $4 million public offering.
    • Mobiquity Technologies, Inc. (NASDAQ:MOBQ) was down, falling 27% to $0.1099 after the company reported pricing of $3 million public offering of 30 million shares of common stock at a price of $0.10/share.

    Also Check This Out: Uber, ON Semiconductor And 2 Other Stocks Insiders Are Selling

     

    Commodities

    In commodity news, oil traded up 0.2% to $69.73 while gold traded down 0.3% at $1,917.00.

    Silver traded down 1.2% to $22.81 on Wednesday while copper fell 1.1% to $3.70.

     

    Euro zone

    European shares closed mixed today. The eurozone’s STOXX 600 rose 0.13%, London’s FTSE 100 fell 0.38% while Spain’s IBEX 35 Index rose 0.31% The German DAX fell 0.01% French CAC 40 rose 0.36% and Italy’s FTSE MIB Index rose 1.05%.

    The services confidence indicator in the Eurozone fell for a second straight month to 5.7 in June, while industry confidence indicator dropped for a fifth consecutive month to -7.2 in June. The consumer confidence indicator in was confirmed at -16.1 for the month, while economic sentiment indicator fell for a second month in a row to 95.3 in June.

    Consumer credit in the UK rose by £1.144 billion in May versus a revised £1.513 billion growth in April. Spain's consumer price inflation fell to 1.9% year-over-year in June.

     

    Asia Pacific Markets

    Asian markets closed mixed on Thursday, with Japan’s Nikkei 225 gaining 0.12%, Hong Kong’s Hang Seng Index falling 1.24%, China’s Shanghai Composite Index slipping 0.22%. India’s S&P BSE Sensex gained 0.8%.

    The consumer confidence index in Japan rose to 36.2 in June versus 36 in the prior month, while retail sales rose by 5.7% year-over-year in May. Retail sales in Australia climbed by 0.7% month-over-month to AUD 35.52 billion in May.

     

    Economics

    • Corporate profits in the U.S. dropped by 5.9% to $2.329 trillion in the first quarter.
    • U.S. initial jobless claims declined by 26,000 from the previous week's 20-month high level to 239,000 during the week ending June 24, recording the sharpest drop since October 2021. However, markets were expecting a reading of 265,000.
    • The U.S. economy expanded by an annualized rate of 2% on quarter in the first quarter, higher than the 1.3% growth in the second estimate, and market expectations of 1.4%.
    • U.S. natural-gas supplies increased 76 billion cubic feet during the week ended June 23.

    Now Read This: Top 2 Utilities Stocks That That Could Sink Your Portfolio This Quarter

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,303,870 cases with around 1,168,100 deaths. India confirmed a total of at least 44,994,140 cases and 531,900 deaths, while France reported over 40,136,340 COVID-19 cases with 167,640 deaths. In total, there were at least 690,913,300 cases of COVID-19 worldwide with more than 6,895,340 deaths.

    Get the next $AYI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AYI
    $BTAI
    $GNLN
    $IMNM

    CompanyDatePrice TargetRatingAnalyst
    BioXcel Therapeutics Inc.
    $BTAI
    3/17/2026$17.00Buy
    Rodman & Renshaw
    Immunome Inc.
    $IMNM
    2/12/2026$40.00Buy
    H.C. Wainwright
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    Acuity Inc.
    $AYI
    10/2/2025$330.00 → $390.00Buy
    TD Cowen
    Immunome Inc.
    $IMNM
    9/22/2025$26.00Buy
    Goldman
    Immunome Inc.
    $IMNM
    9/5/2025$26.00Buy
    Craig Hallum
    Acuity Inc.
    $AYI
    9/2/2025$380.00Equal Weight → Overweight
    Wells Fargo
    Immunome Inc.
    $IMNM
    4/2/2025$23.00Buy
    Lake Street
    More analyst ratings

    $AYI
    $BTAI
    $GNLN
    $IMNM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acuity Reports Fiscal 2026 Second-Quarter Results

    Strong Execution Delivers Sales Growth, Margin Expansion and EPS Improvement Delivered Net Sales of $1.1B, an Increase of 5% Compared to the Prior YearDelivered Operating Profit of $133M, Up 21% Compared to the Prior Year; Grew Adjusted Operating Profit to $176M, Up 8% Compared to the Prior YearDelivered Diluted EPS of $3.09, Up 26% Compared to the Prior Year; Grew Adjusted Diluted EPS to $4.14, Up 11% Compared to the Prior Year ATLANTA, April 02, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI), ("Acuity"), a market-leading industrial technology company, delivered net sales of $1.1 billion in the second quarter, ended February 28, 2026, an increase of $49.4 million, or 4.9 percent, comp

    4/2/26 6:00:00 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Greenlane Holdings, Inc. Announces 1-for-8 Reverse Stock Split

    BOCA RATON, Fla., April 01, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a company with a Berachain-focused Digital Asset Treasury ("DAT"), today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-8, to be effective as of 12:01 a.m. Eastern Time on April 6, 2026. Greenlane's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on April 6, 2026. Following the reverse stock split, Greenlane's common stock will continue to trade on The Nasdaq Capital Market under the symbol "GNLN" with the new CUSIP number, 395330 608. The reverse s

    4/1/26 8:00:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

    PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has a

    4/1/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00

    3/17/26 8:16:49 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Immunome with a new price target

    H.C. Wainwright initiated coverage of Immunome with a rating of Buy and set a new price target of $40.00

    2/12/26 7:24:43 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Immunome with a new price target

    Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00

    12/1/25 8:29:07 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    SEC Filings

    View All

    Greenlane Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Greenlane Holdings, Inc. (0001743745) (Filer)

    4/1/26 8:30:19 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    4/1/26 6:58:25 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenlane Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Greenlane Holdings, Inc. (0001743745) (Filer)

    3/31/26 5:23:08 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    3/12/26 6:05:05 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $149,053 worth of shares (7,278 units at $20.48) and gifted 200,000 shares, decreasing direct ownership by 23% to 660,525 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:38:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Higgins Jack

    4 - Immunome Inc. (0001472012) (Issuer)

    4/1/26 5:39:15 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Siegall Clay B

    4 - Immunome Inc. (0001472012) (Issuer)

    3/31/26 7:11:39 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wagenheim Philip

    4 - Immunome Inc. (0001472012) (Issuer)

    3/23/26 9:23:29 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Leadership Updates

    Live Leadership Updates

    View All

    Greenlane Reports Fourth Quarter and Full Year 2025 Financial Results

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a publicly traded digital asset treasury company focused on the acquisition, management, and strategic deployment of BERA, the native token of the Berachain blockchain network, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Digital Asset Treasury Strategy In October 2025, following the closing of a private placement that raised $110.7M in capital, Greenlane adopted a Treasury Policy and initiated a strategic shift toward a digital asset treasury strategy focused on BERA, the native token of the Berachain blockchain

    3/31/26 5:01:24 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Greenlane Provides Digital Asset Treasury Update: Completes Deployment of Approximately 50 Million Units of BERA

    Total holdings of approximately 70.4 million units of BERA as of February 27, 2026 Up to 50 million units of BERA deployed into validator infrastructure across multiple operators Jason Hitchcock appointed Chief Executive Officer to advance DAT strategy BOCA RATON, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a company with a Berachain-focused Digital Asset Treasury ("DAT"), is providing an update on its holdings of units of BERA and deployment activity. Digital Asset Treasury Holdings Update As of February 27, 2026, the Company held approximately 70.4 million units of BERA1. Since the Company's last treasury update on

    3/3/26 7:30:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Greenlane Appoints Jason Hitchcock as Chief Executive Officer to Advance Digital Asset Treasury Strategy

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN) today announced the appointment of Jason Hitchcock as its Chief Executive Officer, effective immediately. Mr. Hitchcock is a technology executive with over 15 years of experience building and scaling revenue engines across SaaS, blockchain infrastructure, and decentralized finance. He joins Greenlane as the Company continues to execute its Berachain-focused Digital Asset Treasury ("DAT") strategy, combining disciplined capital allocation with active ecosystem participation through validator operations, staking, and liquidity provisioning. Technology Leadership and Ent

    2/18/26 8:00:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mobiquity Technologies Inc.

    SC 13G/A - Mobiquity Technologies, Inc. (0001084267) (Subject)

    11/20/24 7:44:24 PM ET
    $MOBQ
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mobiquity Technologies Inc.

    SC 13G/A - Mobiquity Technologies, Inc. (0001084267) (Subject)

    11/14/24 7:18:49 PM ET
    $MOBQ
    Advertising
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Financials

    Live finance-specific insights

    View All

    Acuity Reports Fiscal 2026 Second-Quarter Results

    Strong Execution Delivers Sales Growth, Margin Expansion and EPS Improvement Delivered Net Sales of $1.1B, an Increase of 5% Compared to the Prior YearDelivered Operating Profit of $133M, Up 21% Compared to the Prior Year; Grew Adjusted Operating Profit to $176M, Up 8% Compared to the Prior YearDelivered Diluted EPS of $3.09, Up 26% Compared to the Prior Year; Grew Adjusted Diluted EPS to $4.14, Up 11% Compared to the Prior Year ATLANTA, April 02, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI), ("Acuity"), a market-leading industrial technology company, delivered net sales of $1.1 billion in the second quarter, ended February 28, 2026, an increase of $49.4 million, or 4.9 percent, comp

    4/2/26 6:00:00 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Acuity Inc. Declares Quarterly Dividend

    Atlanta, March 26, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI) will pay a quarterly dividend of 20 cents per share. The dividend is payable on May 1, 2026, to shareholders of record on April 17, 2026.   About Acuity  Acuity Inc. (NYSE:AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people's lives. We achieve growth through the development of innovative new products and services, including lighting, l

    3/26/26 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    Eco Wave Power Reports Strong Operational Progress and Files 2025 Annual Report on Form 20-F

    Company completes first U.S. wave energy pilot project, submits final report to Shell, records highest energy generation at Israeli project, advances megawatt-scale project in Portugal and supports Taiwan project development, while reducing Q4 operating expenses by 24%Stockholm, Sweden--(Newsfile Corp. - March 12, 2026) - Eco Wave Power Global AB (publ) (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading onshore wave energy technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC").The Annual Report, which includes the Company's aud

    3/12/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities